United Arab Emirates | Imports and Exports | World | Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products | Value (US$) and Value Growth, YoY (%) | 2012 - 2023
The value of exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from United Arab Emirates totalled $ 229 million in 2023. Sales of commodity group 3002 from United Arab Emirates decreased by 39% in value terms compared to 2022. exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" decreased by $ 149 million (cumulative exports of commodity group 3002 from United Arab Emirates amounted $379 million in 2022)
Exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" amounted to 0.04% of total exports from United Arab Emirates (cumulative merchandise exports from United Arab Emirates totalled $ 570 billion in 2023). The share of commodity group 3002 in total exports from United Arab Emirates decreased by 0.033 p.p. compared to 2022 (it was 0.073% in 2022 and cumulative exports from United Arab Emirates were equal to $ 515 billion).
Exports of commodity group 3002 amounted to 12.2% of total sales of group "" from United Arab Emirates in 2023 (the value of exports of commodity group from United Arab Emirates amounted to $1.87 billion in 2023). The share of exports of commodity group 3002 in sales of commodity group from United Arab Emirates lowered by 7.27 p.p. compared to 2022 (it was 19.5% in 2022, and exports of commodity group from United Arab Emirates were $1.94 billion).
Where does United Arab Emirates export Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc?
Top export destinations of "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from United Arab Emirates in 2023:
- Kuwait with a share of 32% (74 million US$)
- Belgium with a share of 16.5% (37 million US$)
- Qatar with a share of 7.88% (18 million US$)
- Iraq with a share of 6.92% (15.8 million US$)
- Lebanon with a share of 5.46% (12.5 million US$)
- Bahrain with a share of 5.19% (11.9 million US$)
- Oman with a share of 4.97% (11.3 million US$)
- Jordan with a share of 4.32% (9.9 million US$)
- Egypt with a share of 3.44% (7.88 million US$)
- India with a share of 3.37% (7.74 million US$)
Exports structure of 3002 - Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc - from United Arab Emirates in 2023 represented by the following main commodity groups:
- 0.282% (647 thousand US$): 300290 - Human blood; animal blood prepared for therapeutic/prophylactic/diagnostic uses; toxins, cultures of micro-organisms (excl. yeasts) & sim. products
The value of imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" to United Arab Emirates totalled $ 1.2 billion in 2023. Sales of commodity group 3002 to United Arab Emirates decreased by 24% in value terms compared to 2022. imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" decreased by $ 400 million (the value of imports of commodity group 3002 to United Arab Emirates was equal to $1.6 billion in 2022)
Imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" accounted for 0.256% of total import flow to United Arab Emirates (in 2023, total imports to United Arab Emirates amounted to $ 470 billion). The share of commodity group 3002 in total imports to United Arab Emirates decreased by 0.125 p.p. compared to 2022 (it was 0.382% in 2022 and cumulative imports to United Arab Emirates were equal to $ 420 billion).
Imports of commodity group 3002 reached 19.5% of total imports of group "" to United Arab Emirates in 2023 (imports of commodity group to United Arab Emirates totalled $6.17 billion in 2023). The share of purchases of commodity group 3002 in imports of commodity group to United Arab Emirates went down by 8.37 p.p. compared to 2022 (it was 27% in 2022, and imports of commodity group to United Arab Emirates accounted for $5.75 billion).
Where does United Arab Emirates import Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc from?
Top trading partners (import of "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc") of United Arab Emirates in 2023:
- USA with a share of 23% (282 million US$)
- Germany with a share of 20% (253 million US$)
- Switzerland with a share of 14.6% (177 million US$)
- France with a share of 7.58% (91 million US$)
- Ireland with a share of 7.25% (87 million US$)
- Belgium with a share of 6.77% (81 million US$)
- Japan with a share of 3.15% (38 million US$)
- Spain with a share of 2.73% (33 million US$)
- Austria with a share of 2.48% (30 million US$)
- Italy with a share of 2.47% (29 million US$)
Imports structure of 3002 - Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc - to United Arab Emirates in 2023 represented by the following main commodity groups:
- 2.13% (25 million US$): 300290 - Human blood; animal blood prepared for therapeutic/prophylactic/diagnostic uses; toxins, cultures of micro-organisms (excl. yeasts) & sim. products
